FDA PMA
FDA Class 3
Approved
🇺🇸 United States
System, Photopheresis, Extracorporeal
PMA: P860003
·
Supplement: S109
·
Decision Mar 13, 2023
Classifications
1
FEI Numbers
11
Registration Numbers
11
Basic Information
- Device Name
- System, Photopheresis, Extracorporeal
- Trade Name
- THERAKOS CELLEX Photopheresis System (CELLEX), THERAKOS CELLEX Photopheresis Procedural Kit (CLXUSA and CLXECP), THERAK
- PMA Number
- P860003
- Supplement Number
- S109
- Device Class
- FDA Class 3
- Product Code
- LNR
- Generic Name
- System, photopheresis, extracorporeal
- Medical Specialty
- Unknown
- Advisory Committee
- Gastroenterology, Urology
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- March 13, 2023
- Date Received
- November 30, 2022
- Supplement Type
- 135 Review Track For 30-Day Notice
- Supplement Reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Expedited Review
- N
Advisory Committee Statement
Approval for a new fixture to replace the current leak tester.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| LNR | System, Photopheresis, Extracorporeal | FDA class 3 | Unknown |